ArticleNon-coding RNA2019
Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129.
Article in Non-coding RNA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- MicroRNA-mediated changes contributing to benzo[a]pyrene toxicity in a 3D respiratory model for asthma.Current research in toxicology · 2026Article
- Prediction of COVID-19 severity using machine learning.Clinical and translational medicine · 2024Article
- Development of a long noncoding RNA-based machine learning model to predict COVID-19 in-hospital mortality.Nature communications · 2024Article
- Article
- A CircRNA-miRNA-mRNA Network for Exploring Doxorubicin- and Myocet-Induced Cardiotoxicity in a Translational Porcine Model.Biomolecules · 2023Article
- Identification of a circulating microRNAs biomarker panel for non-invasive diagnosis of coronary artery disease: case-control study.BMC cardiovascular disorders · 2022Article
- OMICS approaches in cardiovascular diseases: a mini review.Genomics & informatics · 2021Article
- Peripheral blood microRNAs and the COVID-19 patient: methodological considerations, technical challenges and practice points.RNA biology · 2021Review
- Peripheral Blood RNAs and Left Ventricular Dysfunction after Myocardial Infarction: Towards Translation into Clinical Practice.Journal of cardiovascular translational research · 2021Review
- Joining European Scientific Forces to Face Pandemics.Trends in microbiology · 2021Article
- Current Understanding of piRNA in Cardiovascular Diseases.Frontiers in molecular medicine · 2021Review
- RNAs in Brain and Heart Diseases.International journal of molecular sciences · 2020Article
- A Year in the Life of the EU-CardioRNA COST Action: CA17129 Catalysing Transcriptomics Research in Cardiovascular Disease.Non-coding RNA · 2020Article
- Regulatory RNAs in Heart Failure.Circulation · 2020Review
- Challenges in Using Circulating Micro-RNAs as Biomarkers for Cardiovascular Diseases.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors.
Funding
Abstract
Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field.COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.